P19 Incidence and implications of pseudoprogression in women with advanced or recurrent endometrial cancer on pembrolizumab/lenvatinib combination therapy

Sarah Ackroyd,Abbey Knickerbocker,Gustavo Rodriguez,Melissa Lippitt,Elena Diaz Moore,Tilley Jenkins Vogel

Gynecologic Oncology（2023）

引用 0|浏览1

暂无评分

摘要

To describe our experience with pseudoprogression in women with advanced/recurrent endometrial cancer on pembrolizumab/lenvatinib, including latency and duration of response.

查看译文

关键词

recurrent endometrial cancer,pembrolizumab/lenvatinib combination therapy,pseudoprogression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要